Answer
Yes, adverse reactions may be intensified when Cell-based Trivalent Influenza Vaccine Seqirus is given alongside another vaccine, including COVID vaccines; the vaccines should be administered at separate injection sites, preferably on different limbs.
Sources for this answer
- Cell-based Trivalent Influenza Vaccine SeqirusSeqirus UK Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 4Document updated
Sources checked